COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19
T Cihlar, RL Mackman - Antiviral Therapy, 2022 - journals.sagepub.com
If a planned path reaches a dead-end, one can simply stop. Or one can turn around, walk
back to the last intersection and take another path, or one can consider taking few paths in …
back to the last intersection and take another path, or one can consider taking few paths in …
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Abstract Nirmatrelvir/ritonavir (N/R) is one of the most effective antiviral drugs against SARS-
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …
[HTML][HTML] Determination of anti-SARS-CoV-2 virustatic pharmaceuticals in the aquatic environment using high-performance liquid chromatography high-resolution mass …
I Bartels, M Jaeger, TC Schmidt - Analytical and Bioanalytical Chemistry, 2023 - Springer
The Covid-19 pandemic has affected the global population since 2019. The rapid
development and approval of vaccines has brought relief. Yet, effective cures are still being …
development and approval of vaccines has brought relief. Yet, effective cures are still being …
[HTML][HTML] Emerging small molecule antivirals may fit neatly into COVID-19 treatment
C Fenton, SJ Keam - Drugs & Therapy Perspectives, 2022 - Springer
Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although
most are not well established; among these are several small molecule antiviral agents …
most are not well established; among these are several small molecule antiviral agents …
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and
structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome …
structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome …
[HTML][HTML] In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells
Three years after SARS-CoV-2 emerged as a global infectious threat, the virus has become
endemic. The neurological complications such as depression, anxiety, and other CNS …
endemic. The neurological complications such as depression, anxiety, and other CNS …
A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases
RA Leonard, VN Rao, A Bartlett, HM Froggatt… - Journal of …, 2023 - Am Soc Microbiol
Multiple coronaviruses (CoVs) can cause respiratory diseases in humans. While
prophylactic vaccines designed to prevent infection are available for severe acute …
prophylactic vaccines designed to prevent infection are available for severe acute …
Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy
Due to the lack of a method to efficiently represent the multimodal information of a protein,
including its structure and sequence information, predicting compound-protein binding …
including its structure and sequence information, predicting compound-protein binding …
Synthesis and Evaluation of 9-Aminoacridines with SARS-CoV-2 Antiviral Activity
T Jones, N Monakhova, F Guivel-Benhassine… - ACS …, 2023 - ACS Publications
There have been relatively few small molecules developed with direct activity against the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two existing antimalarial …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two existing antimalarial …